CAR-gamma delta T cell therapy - Appia Bio
Alternative Names: CAR-γδTLatest Information Update: 26 Apr 2024
At a glance
- Originator Appia Bio
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Immunological disorders
Most Recent Events
- 15 Apr 2024 Appia Bio has patent protection for its ACUA platform technology (Appia Bio website, April 2024)
- 15 Apr 2024 Preclinical trials in Immunological disorders in USA (Parenteral) before April 2024 (Appia Bio pipeline, April 2024)